Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer
Neill Patani(Institute of Cancer Research), Mitch Dowsett(Institute of Cancer Research), Elizabeth J. Anderson(AstraZeneca (Brazil)), Ricardo Ribas(Institute of Cancer Research), Roger A’Hern, Robert Wellings(AstraZeneca (Brazil)), Anita K. Dunbier(University of Otago), Zara Ghazoui(AstraZeneca (Sweden)), Jill Walker(AstraZeneca (United Kingdom)), Justin P.O. Lindemann(University Hospital Ostrava), Alan Mackay(Institute of Cancer Research), Lesley‐Ann Martin(Institute of Cancer Research), Qiong Gao(Zunyi Medical University), Irene Kuter(Massachusetts General Hospital), H Anderson
Cited by 37
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k